1. Nomenclature of humanized mAbs: Early concepts, current challenges and future perspectives
- Author
-
Patrick Mayrhofer and Renate Kunert
- Subjects
0301 basic medicine ,Computer science ,medicine.drug_class ,Immunology ,International Nonproprietary Name ,Monoclonal antibody ,Antibodies, Monoclonal, Humanized ,Protein Engineering ,antibody immunogenicity ,03 medical and health sciences ,Cdr grafting ,Terminology as Topic ,medicine ,Immunology and Allergy ,Humans ,Nomenclature ,Nomenclature of monoclonal antibodies ,General Medicine ,CDR grafting ,Data science ,USAN ,Complementarity Determining Regions ,030104 developmental biology ,superhumanization ,Primary sequence ,Research Article - Abstract
Nomenclature of monoclonal antibodies traditionally followed a strict scheme indicating target and species information. Because of the rapid advances in this field, emphasized by approval of four humanized and six human antibodies in 2017, the International Nonproprietary Name of new antibodies was updated profoundly by removing the species substem completely. In this review we give an overview about what developments led to the preference of the scientific community towards human-like antibodies. We summarize the major updates in naming schemes that tried to classify antibodies according to their humanization technique or to the final primary sequence and how this led to the erroneous perception to indicate expected immunogenicity. Following the new 2017 nomenclature update, there will not be any information available about the species origin in the names of new antibodies, which emphasizes the need for providing additional supplemental information to the scientific community and develop tools to accurately estimate and control the safety of new monoclonal antibody molecules.
- Published
- 2018